CPIX News and Press, Cumberland Pharmaceuticals Inc.

2024-05-11 23:51:04 ET Start Time: 15:30 End Time: 15:59 Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Conference Call May 07, 2024, 15:30 PM ET Company Participants A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO...

2024-05-07 16:39:08 ET More on Cumberland Pharmaceuticals Financial information for Cumberland Pharmaceuticals Read the full article on Seeking Alpha For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of -$0.05, revenue of $8.5M

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update PR Newswire NASHVILLE, TENN . , May 7, 2024 /PRNewswire/ -- Cumberland Ph...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release ...

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS PR Newswire Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , Ap...

2024-03-05 22:06:02 ET Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Conference Call March 05 2024 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman and Chief Executive Officer Todd Anthony - Vice P...

2024-03-05 16:13:46 ET More on Cumberland Pharmaceuticals Financial information for Cumberland Pharmaceuticals Read the full article on Seeking Alpha For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of $0.17, revenue of $40M

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results PR Newswire 2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a sp...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...